Metastatic Breast Cancer Clinical Trials in Phoenix, Arizona

4 studies are recruiting for metastatic breast cancer in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary …

    Stage
    Phase 3
    Ages
    60 and older
    Site
    Ironwood Cancer & Research Centers, Phoenix, Arizona
    Locations
    73 in total
    Run by
    American Society of Clinical Oncology

    See if you can join NCT06377852 on ClinicalTrials.gov

  2. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona
    Locations
    10 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

  3. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix, Arizona
    Locations
    79 in total
    Run by
    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

  4. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines o…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic Hospital, Phoenix, Arizona
    Locations
    53 in total
    Run by
    Puma Biotechnology, Inc.

    See if you can join NCT06369285 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.